Skip navigation

Factor XII (Hageman factor) deficiency

Factor XII deficiency is an inherited disorder that affects a protein (factor XII) involved in blood clotting.

Causes

When you bleed, the body launches a series of reactions that help the blood clot. This is called the coagulation cascade. The process involves special proteins called coagulation factors. (Factor XII is a coagulation factor in this series of reactions.)

Each factor has a reaction that triggers the next reaction. The final product of the coagulation cascade is the blood clot. When one or more of these clotting factors are missing, there is usually a higher chance of bleeding.

A lack of factor XII does not cause the affected person to bleed abnormally, but the blood takes longer than normal to clot in a test tube.

Factor XII deficiency is a rare inherited disorder.

Symptoms

There are usually no symptoms.

Exams and Tests

Factor XII deficiency is usually found when clotting tests are done for routine screening.

Tests may include:

Treatment

Treatment is usually not needed.

Outlook (Prognosis)

The outcome is expected to be good without treatment.

Possible Complications

There are usually no complications.

When to Contact a Medical Professional

The health care provider usually discovers this condition after noticing prolonged clotting in the process of running other laboratory tests.

Prevention

This is an inherited disorder. There is no known way to prevent it.

References

Gailani D, Neff AT. Rare coagulation factor deficiencies. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier;2008:chap 127.

Kessler C. Hemorrhagic disorders: Coagulation factor deficiencies. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 180.

Update Date: 2/28/2011

Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

MedlinePlus Topics

Images

A.D.A.M Quality Logo

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2014, A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.

A.D.A.M Logo